Mathew C. Bazley
Keine laufenden Positionen mehr
Profil
Mathew C.
Bazley worked as the President, Secretary & Chief Liquidation Officer at Savient Pharmaceuticals, Inc. and as the General Counsel at Sio Gene Therapies, Inc.
Ehemalige bekannte Positionen von Mathew C. Bazley
| Unternehmen | Position | Ende |
|---|---|---|
| SIO GENE THERAPIES INC. | General Counsel | 01.09.2019 |
| SAVIENT PHARMACEUTICALS INC | Präsident | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Savient Pharmaceuticals, Inc.
 Savient Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Savient Pharmaceuticals, Inc. operates as a specialty biopharmaceutical company, which develops, manufactures and markets pharmaceutical products. The company focuses on developing and commercializing KRYSTEXXA for the treatment of chronic gout in adult patients who do not respond to conventional therapy. It also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. The company was founded in 1980 is headquartered in East Brunswick, NJ. | Health Technology |
Sio Gene Therapies, Inc.
 Sio Gene Therapies, Inc. Pharmaceuticals: MajorHealth Technology Sio Gene Therapies, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. The company was founded on October 31, 2014 and is headquartered in New York, NY. | Health Technology |
